Table 2.
Effect of Spirulysat® supplementation on different clinical parameters in studied subjects.
| Measured Variables | V1 | V2 | V3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo n = 20 | Spirulysat® n = 20 | p-Value | Placebo n = 20 | Spirulysat® n = 20 | p-Value | Placebo n = 20 | Spirulysat® n = 20 | p-Value | |
| oxLDL/LDL cholesterol ratio (U/g) | 67.44 ± 23.04 | 61.15 ± 20.53 | 0.58 | 72.22 ± 17.76 | 67.16 ±14.37 | 0.41 | 74.06 ± 16.08 | 69.08 ± 12.72 | 0.36 |
| Triglycerides (g/L) | 1.83 ± 0.82 | 1.35 ± 0.46 | 0.11 | 2.02 ± 0.89 | 1.58 ± 0.80 | 0.13 | 1.97 ± 0.80 | 1.23 ± 0.57 | 0.003 |
| LDL cholesterol (g/L) | 1.53 ± 0.36 | 1.52 ± 0.33 | 0.88 | 1.51 ±0.44 | 1.49 ± 0.32 | 0.96 | 1.43 ± 0.38 | 1.49 ± 0.33 | 0.22 |
| HDL cholesterol (g/L) | 0.47 ± 0.13 | 0.54 ± 0.09 | 0.004 | 0.47 ± 0.16 | 0.54 ± 0.11 | 0.012 | 0.48 ± 0.18 | 0.55 ± 0.14 | 0.031 |
| Total cholesterol (g/L) | 2.36 ± 0.46 | 2.33 ± 0.36 | 0.96 | 2.38 ± 0.50 | 2.34 ± 0.35 | 0.77 | 2.31 ± 0.43 | 2.30 ± 0.34 | 0.57 |
| Fatty Liver Index ( FLI) | 72.95 ± 15.39 | 68.90 ± 19.89 | 0.71 | 74.25 ± 16.46 | 69.18 ± 20.36 | 0.48 | 75.32 ± 17.53 | 65.63 ± 22.16 | 0.19 |
| Glycemia (mmol/L) | 5.26 ± 0.64 | 5.56 ± 0.56 | 0.072 | 5.48 ± 0.76 | 5.55 ± 0.65 | 0.84 | 5.38 ± 0.76 | 5.90 ± 0.67 | 0.056 |
| Insulinemia (mU/L) | 10.06 ± 4.78 | 14.17 ± 8.11 | 0.044 | 11.39 ± 3.41 | 13.89 ± 6.60 | 0.33 | 11.95 ± 4.82 | 16.13 ± 10.88 | 0.28 |
| Urinary isoprostane (µg/24 h) | 2.86 ± 1.96 | 2.61 ±1.44 | 0.82 | 2.98 ± 1.56 | 2.20 ± 1.09 | 0.057 | 3.51 ± 2.11 | 2.31 ± 0.91 | 0.014 |
| ALAT (µkat/L) | 0.48 ± 0.31 | 0.59 ± 0.35 | 0.27 | 0.45 ± 0.23 | 0.57 ± 0.33 | 0.16 | 0.62 ± 0.58 | 0.57 ± 0.48 | 0.7 |
| ASAT (µkat/L) | 0.41 ± 0.14 | 0.43 ± 0.14 | 0.63 | 0.42 ± 0.13 | 0.42 ± 0.15 | 0.85 | 0.49 ± 0.30 | 0.43 ± 0.16 | 0.64 |
| GGT (U/L) | 50.22 ± 50.07 | 46.84 ± 34.97 | >0.99 | 45.67 ± 37.75 | 45.23 ± 28.84 | 0.69 | 54.64 ± 59.04 | 49.07 ± 36.69 | 0.54 |
Missing data for fatty liver index (FLI) (n = 4; placebo = 1, Spirulysat® = 3); glycemia (n = 1); insulinemia (n = 1); urinary isoprostane (Spirulysat®, n = 2); urinary isoprostane (Spirulysat, n = 2). Results are presented as Mean (SD); Wilcoxon rank sum test. oxLDL: oxidized low-density lipoprotein, LDL: low density lipoprotein, HDL: high density lipoprotein, ALAT: alanine aminotransferase, ASAT: aspartate aminotransferase, GGT (gamma-glutamyltransferases).